Expert Review of Gastroenterology & Hepatology最新文献_第5页

Before the scope: precision medicine in medication management for endoscopic safety and quality. 前scope：精准医学在用药管理中注重内镜的安全和质量。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-05-01 Epub Date: 2026-04-30 DOI: 10.1080/17474124.2026.2665306

Syed Anjum Gardezi, Fuad Muafa, Mohammad Al Awamy, Zahrah Al Omran, Antonio Facciorusso, Eyad Gadour

{"title":"Before the scope: precision medicine in medication management for endoscopic safety and quality.","authors":"Syed Anjum Gardezi, Fuad Muafa, Mohammad Al Awamy, Zahrah Al Omran, Antonio Facciorusso, Eyad Gadour","doi":"10.1080/17474124.2026.2665306","DOIUrl":"10.1080/17474124.2026.2665306","url":null,"abstract":"Introduction: Medication management is central to endoscopic safety because comorbidities, polypharmacy, and variable drug responses can substantially influence procedural risk. This review examines how a precision medicine approach can improve peri-endoscopic decision-making and patient outcomes.Areas covered: A structured literature review of PubMed/MEDLINE, Embase, and the Cochrane Library (2000-2025) evaluated evidence on medications and supplements affecting endoscopic safety and efficacy. The review examined drug classes influencing bleeding, sedation, bowel preparation, aspiration, metabolic stability, and diagnostic accuracy, with emphasis on individualized management strategies.Expert opinion: Precision-based medication review should be embedded in routine endoscopy practice through multidisciplinary collaboration, structured reconciliation, and risk stratification. Wider adoption of pharmacogenomic-informed and individualized protocols may reduce preventable complications, improve diagnostic quality, and support safer, more patient-centered care.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"475-483"},"PeriodicalIF":3.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the efficacy and future prospects of nutritional and dietary therapies in Crohn's disease. 探讨营养和饮食治疗克罗恩病的疗效和未来前景。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-05-01 Epub Date: 2026-04-30 DOI: 10.1080/17474124.2026.2667874

Takayuki Yamamoto

{"title":"Exploring the efficacy and future prospects of nutritional and dietary therapies in Crohn's disease.","authors":"Takayuki Yamamoto","doi":"10.1080/17474124.2026.2667874","DOIUrl":"10.1080/17474124.2026.2667874","url":null,"abstract":"Introduction: Nutritional therapy has progressed from supportive care to a targeted strategy in inflammatory bowel disease (IBD), particularly Crohn's disease (CD). Exclusive enteral nutrition (EEN) is firmly established as a first-line induction therapy in pediatric CD, achieving remission rates comparable to corticosteroids while simultaneously supporting growth and promoting mucosal healing.Areas covered: This review outlines enteral and dietary interventions in CD. A PubMed (MEDLINE) search identified relevant studies on nutritional and dietary interventions in CD published up to 17 August 2025. In children, EEN is validated; in adults, its use is more selective, with evidence supporting benefit in mild-to-moderate disease, intolerance to pharmacologic agents, and perioperative optimization. Elemental or low-residue formulas are particularly relevant for patients with stricturing disease or malnutrition. Partial enteral nutrition and structured exclusion diets, such as the Crohn's Disease Exclusion Diet (CDED), offer feasible long-term approaches. Regional differences persist, as Japan has established reimbursement pathways facilitating enteral nutrition, whereas Western countries generally prioritize pharmacologic therapies.Expert opinion: Enteral nutrition remains a valuable therapeutic option in CD when applied to carefully selected patients. Although biologics and small molecules dominate current management, individualized patient selection, adherence support, and multidisciplinary education are critical to maximize its therapeutic impact.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"425-437"},"PeriodicalIF":3.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastric acid secretion therapy: long-term effects on gastric mucosa and polyp formation. 胃酸分泌疗法：对胃黏膜及息肉形成的长期影响。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-05-01 Epub Date: 2026-03-26 DOI: 10.1080/17474124.2026.2650654

Hiroko Suda, Koichi Sakurai, Ken Haruma

{"title":"Gastric acid secretion therapy: long-term effects on gastric mucosa and polyp formation.","authors":"Hiroko Suda, Koichi Sakurai, Ken Haruma","doi":"10.1080/17474124.2026.2650654","DOIUrl":"10.1080/17474124.2026.2650654","url":null,"abstract":"Introduction: Proton pump inhibitors (PPIs) and potassium-competitive acid blockers (P-CABs) are widely used for the management of acid-related disorders. Characteristic gastric mucosal changes have gained clinical attention owing to their widespread and prolonged use.Areas covered: We outline the pharmacological differences between PPIs and P-CABs and we summarize their endoscopic and histological features. Hypergastrinemia is highlighted as a central mediator, interacting with factors including Helicobacter pylori infection, atrophic gastritis, age, and sex. Evidence from randomized and observational studies, case series, and mechanistic investigations has been integrated to provide an overview of the long-term effects of these therapies.Expert opinion: Most reported mucosal alterations, including fundic gland polyps, hyperplastic polyps, multiple white and flat elevated lesions, cracked or cobblestone-like mucosa, black spots, gastric mucosal redness, white spots, and web-like mucus, are considered benign. Although endoscopic surveillance is not currently supported by evidence, awareness of these findings may be useful in patients receiving therapy for several decades. Endoscopic features,-associated with hypergastrinemia and parietal- or enterochromaffin-like cell proliferation, may serve as tools to guide individualized prescribing and deprescribing strategies. Further research should include decade-long cohort studies, studies comparing PPIs and P-CABs, and trials evaluating on-demand and continuous regimens to optimize long-term safety.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"395-407"},"PeriodicalIF":3.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147510889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical role of anti-PD-1 immunotherapies in esophageal cancer. 抗pd -1免疫治疗在食管癌中的临床作用。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-04-01 Epub Date: 2026-03-22 DOI: 10.1080/17474124.2026.2646298

Momoko Sano, Hiroshi Imazeki, Shun Yamamoto, Ken Kato

{"title":"Clinical role of anti-PD-1 immunotherapies in esophageal cancer.","authors":"Momoko Sano, Hiroshi Imazeki, Shun Yamamoto, Ken Kato","doi":"10.1080/17474124.2026.2646298","DOIUrl":"10.1080/17474124.2026.2646298","url":null,"abstract":"Introduction: Anti-PD-1 antibodies in pharmacotherapy for esophageal cancer have caused a paradigm shift in the treatment strategy. New evidence is being generated not only for metastatic or recurrent cases, but also in the perioperative setting, and the role of anti-PD-1 antibodies in the treatment of esophageal cancer will continue to increase.Areas covered: This review summarizes the clinical role of approved anti-PD-1 antibodies, including nivolumab and pembrolizumab, and discusses additional agents supported by phase 3 evidence. We emphasize current standards of care across metastatic and perioperative settings while briefly addressing emerging strategies under clinical evaluation.Expert opinion: Anti-PD-1 antibodies containing therapies have become central to ESCC management, improving survival in both metastatic and perioperative settings. Regional phase 3 trials have expanded therapeutic options, although differences in regulatory approval influence global accessibility. Despite these advances, optimal patient selection remains challenging, and predictive biomarkers are urgently needed. Future progress will depend on biomarker development, treatment sequencing, and integration of emerging strategies supported by robust clinical evidence.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"325-334"},"PeriodicalIF":3.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147473155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A critical review of technical progress, clinical heterogeneity, and implementation challenges of artificial intelligence in digestive endoscopy. 人工智能在消化内窥镜检查中的技术进步、临床异质性和实施挑战。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-04-01 Epub Date: 2026-03-23 DOI: 10.1080/17474124.2026.2646299

Eyad Gadour, Bodour Raheem, Antonio Facciorusso

{"title":"A critical review of technical progress, clinical heterogeneity, and implementation challenges of artificial intelligence in digestive endoscopy.","authors":"Eyad Gadour, Bodour Raheem, Antonio Facciorusso","doi":"10.1080/17474124.2026.2646299","DOIUrl":"10.1080/17474124.2026.2646299","url":null,"abstract":"Introduction: Digestive endoscopy is a critical modality for diagnosing and managing gastrointestinal diseases, yet it faces challenges including operator dependence, procedural complexity, and potential complications. Artificial intelligence (AI) has emerged as a promising adjunct to address these limitations by enhancing diagnostic accuracy and optimizing procedural workflows.Areas covered: This review comprehensively examines the application of AI across diverse clinical practices in digestive endoscopy. Key areas include lesion detection and diagnosis, lesion characterization and classification, quality control, workflow optimization, and therapeutic guidance. Additionally, it highlights the principal AI technologies that have received regulatory approval from the Food and Drug Administration (FDA) and European CE marking, underscoring their clinical readiness and integration potential.Expert opinion: AI demonstrates significant potential to improve endoscopic outcomes by augmenting lesion detection rates and diagnostic precision. However, the translation of AI innovations into routine clinical practice is tempered by challenges, such as variability in clinical effectiveness, dependency on procedural quality, domain generalizability, and cost-effectiveness considerations. Future advancements should focus on enhancing AI robustness, integrating multimodal data, and establishing sustainable implementation frameworks to maximize clinical benefit while maintaining patient safety and ethical standards.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"335-351"},"PeriodicalIF":3.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147467549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Short bowel syndrome-associated intestinal failure: diagnosis and prognosis. 短肠综合征相关肠衰竭：诊断和预后。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-04-01 Epub Date: 2026-03-17 DOI: 10.1080/17474124.2026.2646296

John K DiBaise

{"title":"Short bowel syndrome-associated intestinal failure: diagnosis and prognosis.","authors":"John K DiBaise","doi":"10.1080/17474124.2026.2646296","DOIUrl":"10.1080/17474124.2026.2646296","url":null,"abstract":"Introduction: Short bowel syndrome is characterized by severe intestinal malabsorption of macronutrients, micronutrients, fluid, and electrolytes. As such, short bowel syndrome often results in permanent need of parenteral support, that is, intestinal failure. To optimize patient outcomes, it is important to establish precise definitions of short bowel syndrome and intestinal failure. Classifying those with SBS can provide useful prognostic, risk and therapeutic implications.Areas covered: This narrative review will focus on the diagnosis and prognosis of this rare condition. A literature search was performed utilizing PubMed and reviewed references from applicable manuscripts primarily between 2000 and September 2025.Expert opinion: Short bowel syndrome in adults is a clinical malabsorptive syndrome associated with having <200 cm of residual small bowel in continuity, measured from the duodenojejunal flexure. Intestinal failure is the reduction of gut function below the minimum required for the absorption of macronutrients and/or water and electrolytes, thereby requiring parenteral support to maintain health and/or growth. The remaining small bowel length and segment, and health of the remnant bowel have important prognostic implications. Care gaps exist regarding the diagnosis and management of this condition and future efforts should address these disparities in order to provide optimal care to these patients.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"313-323"},"PeriodicalIF":3.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147443044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Key mistakes in alcohol-associated liver disease management and how to avoid them: a narrative review. 酒精相关性肝病管理中的主要错误及如何避免：叙述性回顾

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-04-01 Epub Date: 2026-03-28 DOI: 10.1080/17474124.2026.2649801

Madunil Anuk Niriella, Renisha Chrismi Karunanayake, Mananjala Sudul Senanayake, Uditha Bandara Dassanayake, Chamara Wijesinghe, Hithanadura Janaka de Silva

{"title":"Key mistakes in alcohol-associated liver disease management and how to avoid them: a narrative review.","authors":"Madunil Anuk Niriella, Renisha Chrismi Karunanayake, Mananjala Sudul Senanayake, Uditha Bandara Dassanayake, Chamara Wijesinghe, Hithanadura Janaka de Silva","doi":"10.1080/17474124.2026.2649801","DOIUrl":"10.1080/17474124.2026.2649801","url":null,"abstract":"Introduction: Alcohol-associated liver disease (ALD) encompasses a spectrum from simple steatosis through fibrosis, cirrhosis, and hepatocellular carcinoma. Alcohol-associated hepatitis (AH) represents a severe acute manifestation of ALD carrying substantial short-term mortality. ALD is strongly associated with harmful alcohol use and alcohol use disorder (AUD), though a proportion of patients may engage in hazardous drinking patterns that do not meet full DSM-5 criteria for AUD. Despite being a considerable global health burden, ALD frequently remains underdiagnosed until advanced stages.Areas covered: This narrative review examines critical deficiencies in the management of ALD and AUD, from initial recognition through long-term follow-up. This review is informed by structured searches of PubMed/MEDLINE, Embase, and Cochrane Library (2005-2025). Commonly identified pitfalls include delayed screening for AUD, inadequate assessment of consumption patterns, mismanagement of episodes of AH, neglect of nutritional requirements, suboptimal pharmacological approaches, and poor coordination among multidisciplinary teams (MDT). By highlighting recurrent mistakes and providing evidence-based strategies to avoid them, this narrative review aims to equip clinicians with practical tools to improve patient outcomes.Expert opinion: The future of ALD management lies at the intersection of technological innovation, therapeutic advancement, systems-level care redesign, and public health policy.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"353-367"},"PeriodicalIF":3.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147485218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evolving role of futibatinib for advanced cholangiocarcinoma. 福替替尼在晚期胆管癌中的作用。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-04-01 Epub Date: 2026-03-25 DOI: 10.1080/17474124.2026.2649804

Mara Persano, Andrea Casadei-Gardini, Silvia Camera, Margherita Rimini

{"title":"The evolving role of futibatinib for advanced cholangiocarcinoma.","authors":"Mara Persano, Andrea Casadei-Gardini, Silvia Camera, Margherita Rimini","doi":"10.1080/17474124.2026.2649804","DOIUrl":"10.1080/17474124.2026.2649804","url":null,"abstract":"Introduction: Cholangiocarcinoma (CCA) continues to be classified as a rare cancer with high mortality rates, underscoring the urgent need for more effective systemic treatment strategies. The widespread implementation of next-generation sequencing has enabled comprehensive characterization of the genomic landscape of CCA, revealing a relatively high prevalence of actionable genetic alterations.Areas covered: In this evolving therapeutic context, futibatinib has gained attention as a selective, irreversible pan-fibroblast growth factor receptor (FGFR) inhibitor that covalently binds to the FGFR kinase domain, thereby maintaining inhibitory activity against a broad spectrum of FGFR2 resistance mutations. This distinct mechanism of action represents a significant advancement over earlier reversible inhibitors and provides a strong biological rationale for its use in patients with FGFR2-altered CCA. A comprehensive literature search was performed in PubMed/MEDLINE, Embase, and Scopus for studies published from January 2000 to February 2026, using combinations of the terms 'cholangiocarcinoma,' 'FGFR2,' 'fibroblast growth factor receptor,' and 'futibatinib.' Relevant clinical trials, translational studies, and review articles were screened for inclusion.Expert opinion: Futibatinib represents the most biologically rational FGFR inhibitor currently available for FGFR2-altered CCA, as it directly addresses the dominant mechanism limiting the efficacy of earlier agent, on-target resistance driven by secondary FGFR2 kinase domain mutations.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"369-379"},"PeriodicalIF":3.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147497899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ulcerative colitis, frailty, and beyond. 溃疡性结肠炎、身体虚弱等等。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-04-01 Epub Date: 2026-03-18 DOI: 10.1080/17474124.2026.2645570

Yushan Pan, Bharati Kochar

{"title":"Ulcerative colitis, frailty, and beyond.","authors":"Yushan Pan, Bharati Kochar","doi":"10.1080/17474124.2026.2645570","DOIUrl":"10.1080/17474124.2026.2645570","url":null,"abstract":"Introduction: Frailty is a geriatric construct that is increasingly pertinent to patients with ulcerative colitis (UC). Understanding how frailty and UC interact will be imperative to incorporating frailty into clinical decision-making in UC.Areas covered: This article reviews the definition of frailty and its contributing factors. We review the mechanisms in which UC leads to frailty and the current literature on the impact of frailty status in UC disease course. This review was conducted through PubMed searches using the terms 'ulcerative colitis,' 'frailty,' 'sarcopenia,' 'inflammation,' 'multimorbidity,' and 'aging' with no time restrictions.Expert opinion: Frailty is a prevalent feature in UC and is partly mediated by the chronic inflammation and sarcopenia that characterize UC. Preliminary evidence suggests that frailty may prognosticate outcomes in patients with UC, but more work is needed to define features of frailty pertinent to inflammatory bowel disease, develop and validate measures tailored to assessing frailty in patients with UC, and implement frailty into clinical decision-making for the management of UC.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"303-311"},"PeriodicalIF":3.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147480093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-dosage human albumin infusion may be superior for hypervolemic hyponatremia in cirrhosis with ascites. 大剂量人白蛋白输注可能对肝硬化伴腹水的高血容量性低钠血症更有效。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-03-01 Epub Date: 2025-11-17 DOI: 10.1080/17474124.2025.2587292

Xianxian Zhang, Lu Chai, Haonan Zhao, Haitao Zhao, Ran Wang, Mauro Bernardi, Xingshun Qi

{"title":"High-dosage human albumin infusion may be superior for hypervolemic hyponatremia in cirrhosis with ascites.","authors":"Xianxian Zhang, Lu Chai, Haonan Zhao, Haitao Zhao, Ran Wang, Mauro Bernardi, Xingshun Qi","doi":"10.1080/17474124.2025.2587292","DOIUrl":"10.1080/17474124.2025.2587292","url":null,"abstract":"Background: Human albumin (HA) infusion may be effective for improving hypervolemic hyponatremia in cirrhosis. However, it remains unclear about whether HA dosage can influence its efficacy.Methods: Overall, 288 cirrhotic patients with ascites and hypervolemic hyponatremia were retrospectively included and divided into high-dosage (>80 g) and low-dosage (≤80 g) HA groups during the period from the first hyponatremia diagnosis to the last HA infusion. Multivariate logistic regression analyses were performed to explore the impact of HA dosage on hyponatremia and serum albumin (ALB) level, and evaluate the impact of improvement of ALB on hyponatremia. Subgroup analyses were performed according to the baseline serum ALB level.Results: High-dosage HA was independently associated with normalization of hyponatremia (OR = 1.919, p = 0.040) and improvement of ALB (OR = 3.001, p < 0.001). The effect of high-dosage HA on normalization of hyponatremia (OR = 2.108, p = 0.028) and improvement of ALB (OR = 2.926, p = 0.001) remained significant in patients with a baseline ALB level of <30 g/L. Improvement of ALB was independently associated with normalization of hyponatremia (OR = 2.108, p = 0.014). The effect remained significant in patients with a baseline ALB level of <30 g/L (OR = 2.228, p = 0.019).Conclusions: High-dosage HA should be superior to low-dosage HA for correcting hypervolemic hyponatremia in cirrhosis, especially in those with a baseline ALB level of <30 g/L, probably due to its significant benefit in the improvement of ALB.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"289-301"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145451367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0